Dupixent hits all endpoints in prurigo nodularis trial
Dupixent significantly reduced itch and skin lesions compared to placebo in the investigational trial setting
Read More
Tag: prurigo nodularis
Galderma’s investigational prurigo nodularis drug hits Phase II endpoint
Prurigo nodularis is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
